A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

• Threshold value of handheld Health Management Tool (HMT) for choroidal neovascular AMD diagnosis at baseline [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
• Identification of clinically relevant worsening of visual function in the home self testing mVT scores [ Time Frame: baseline to 16 weeks ] [ Designated as safety issue: No ]

• Correlation of the handheld Health Management Tool (HMT) home self testing on the days of site visits and the mVT assessments performed during the site visits for absolute values [ Time Frame: after 16 weeks ] [ Designated as safety issue: No ]
• Correlation between the home deterioration signal and the monthly change in the handheld Health Management Tool (HMT) assessments performed during the site visits [ Time Frame: after 16 weeks ] [ Designated as safety issue: No ]
• Patient compliance and reliability of performing the home self testing using the handheld Health Management Tool (HMT) [ Time Frame: after 16 weeks ] [ Designated as safety issue: No ]
• Correlation between absolute values of the handheld Health Management Tool (HMT) and BCVA/ central retinal subfield thickness (CRST) [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
• Correlation of the monthly changes in handheld Health Management Tool(HMT)to those of BCVA / OCT / Clinical examination [ Time Frame: after 16 weeks ] [ Designated as safety issue: No ]
• Correlation of diagnosis of choroidal neovascular AMD with BCVA/ central retinal subfield thickness [ Time Frame: baseline ] [ Designated as safety issue: No ]
  The disease diagnoses at baseline will be correlated to values of BCVA and CRST at baseline
• Correlation of monthly changes observed within the investigator judgment (CJ-C) to BCVA / OCT / Clinical examination [ Time Frame: baseline to 16 weeks ] [ Designated as safety issue: No ]
  Monthly changes in BCVA /OCT and clinical examination will be compared to clinical relevant changes as judged by the investigator on the CJC.
• Patient compliance with the signs and symptom questionnaire [ Time Frame: baseline to 16 weeks ] [ Designated as safety issue: No ]
  The percentage of completed assessments of the signs & symptoms questionnaire on the HMT will be provided
• Patient satisfaction regarding the use of the HMT [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]

This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular Degeneration (AMD) to detect a potential change in disease status.

Inclusion Criteria:

• Patients with CNV secondary to AMD and not other causes in at least one eye identified by the investigator to be eligible for ranibizumab treatment
• Patients with a BCVA letter score in the study eye is 24 or better using an ETDRS chart measured at 4 meters distance

Exclusion Criteria:

• Patients with any concurrent ocular condition that may result in visual loss during the study
• Patients with past (within the prior 6 months) or current use of, or likely need for, systemic medications that are known to be toxic to the lens, retina, or optic nerve
• Other protocol-defined inclusion/exclusion criteria may apply